comparemela.com
Home
Live Updates
ARBs and Cancer Risk: New Meta-Analysis Raises Questions Again : comparemela.com
ARBs and Cancer Risk: New Meta-Analysis Raises Questions Again
The trial-level analysis suggests a dose-response relationship between exposure to angiotensin receptor blockers and the risk for cancer, reawakening previous questions on this issue.
Related Keywords
Bern
,
Switzerland
,
Pennsylvania
,
United States
,
Istanbul
,
Turkey
,
Acibadem
,
Elazig
,
American
,
Andrew Althouse
,
Ilke Sipahi
,
George Bakris
,
Franz Messerli
,
Steve Nissen
,
Thomas Marciniak
,
Acibadem University Medical School
,
University Of Pittsburgh
,
University Of Bern
,
Drug Administration
,
University Of Chicago Medicine
,
Lancet Oncology
,
Medscape Cardiology
,
Cleveland Clinic
,
Chicago Medicine
,
Hypertension
,
Cancer
,
Alignant Neoplasia
,
Arcinoma
,
Patient Safety
,
Cancer Risk
,
Angiotensin Ii Receptor Blockade
,
Clinical Research
,
Clinical Trials
,
Linical Studies
,
Meta Analysis
,
Us Food And Drug Administration
,
Nited States Food And Drug Administration
,
Fda
,
Lung Cancer
,
Ung Carcinoma
,
Ancer Lung
,
Smoking
,
Smoker
,
Tobacco Cessation
,
Uitting Tobacco Use
,
Antihypertensive
,
Cardiovascular Disease
,
comparemela.com © 2020. All Rights Reserved.